The Manufacturers Life Insurance Company Has $951.49 Million Stock Position in Johnson & Johnson $JNJ

Key Points

• The Manufacturers Life Insurance Company increased its Johnson & Johnson stake by 5.1% in the second quarter, bringing its holdings to 3.75 million shares valued at approximately $951.5 million. Institutional investors and hedge funds collectively own 69.55% of JNJ.
• Johnson & Johnson exceeded quarterly earnings and revenue expectations, reporting $2.90 in EPS and $25.31 billion in revenue. The company reaffirmed FY 2026 EPS guidance of $11.60–$11.75 and pays an annualized dividend of $5.36, yielding about 2%.
• Analysts maintain a generally positive outlook, with JNJ receiving a “Moderate Buy” consensus rating and an average price target of $274.13. However, recent insider selling and a failed Phase 2 depression-drug trial represent potential cautionary signals.

The Manufacturers Life Insurance Company lifted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,746,452 shares of the company's stock after purchasing an additional 180,724 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.16% of Johnson & Johnson worth $951,486,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in JNJ. Blueline Advisors LLC bought a new position in Johnson & Johnson in the fourth quarter worth approximately $25,000. Outlook Capital Management LLC bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $28,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $37,000. Matrix Trust Co raised its position in shares of Johnson & Johnson by 56.2% during the second quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after purchasing an additional 54 shares during the period. Finally, Hyposwiss Advisors SA bought a new position in shares of Johnson & Johnson in the 4th quarter worth $42,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.1%

JNJ stock opened at $267.35 on Thursday. The stock has a market cap of $644.28 billion, a P/E ratio of 30.98, a P/E/G ratio of 2.55 and a beta of 0.24. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The stock's fifty day simple moving average is $263.25 and its two-hundred day simple moving average is $246.40. Johnson & Johnson has a 1-year low of $173.33 and a 1-year high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. The company had revenue of $25.31 billion for the quarter, compared to analysts' expectations of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts expect that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were given a $1.34 dividend. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson's payout ratio is currently 62.11%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on JNJ shares. Royal Bank Of Canada boosted their price target on shares of Johnson & Johnson from $265.00 to $287.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Wells Fargo & Company raised their price objective on shares of Johnson & Johnson from $272.00 to $282.00 and gave the company an "overweight" rating in a research note on Monday, August 3rd. Wall Street Zen cut shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. UBS Group began coverage on shares of Johnson & Johnson in a report on Wednesday, September 2nd. They issued a "buy" rating and a $320.00 target price on the stock. Finally, Bank of America raised their price target on shares of Johnson & Johnson from $254.00 to $263.00 and gave the company a "neutral" rating in a research report on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and an average price target of $274.13.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Vanessa Broadhurst sold 23,054 shares of the company's stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 87,569 shares of company stock valued at $23,064,544 in the last three months. Insiders own 0.16% of the company's stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Promising lung-cancer results strengthen J&J’s growth outlook. New Phase 2b and Phase 3 data showed that RYBREVANT-based combinations for EGFR-mutated non-small-cell lung cancer delivered improved tolerability, fewer treatment-related adverse events and longer reported overall survival. The results could support adoption of RYBREVANT and LAZCLUZE in first-line treatment. Johnson & Johnson Reports Stronger Survival Data in EGFR-Mutated Lung Cancer
• Positive Sentiment: Underlying business momentum remains resilient despite STELARA pressure. Management said sales increased 5.6% excluding the roughly 460-basis-point drag from STELARA, encouraging investors to focus on growth from the broader pharmaceutical and MedTech portfolios. The company previously reported quarterly revenue of $25.31 billion, up 6.6% year over year, and adjusted EPS above consensus. Should You Judge JNJ Stock Without STELARA?
• Positive Sentiment: Potential value creation from a DePuy Synthes sale is attracting investor interest. Apollo Global Management is reportedly considering acquiring J&J’s orthopedics business for close to $20 billion. A transaction could unlock value, sharpen J&J’s portfolio focus and provide capital for acquisitions or shareholder returns, although no deal has been announced. Apollo and J&J Face a High-Stakes Orthopedics Deal
• Neutral Sentiment: J&J remains viewed as a defensive, dividend-oriented healthcare holding. Its roughly 2% yield, recent outperformance and FY 2026 EPS guidance of $11.60–$11.75 support the investment case, but a valuation near 31 times earnings leaves less room for execution disappointments.
• Negative Sentiment: A partnered depression drug failed a key Phase 2 endpoint. Contineum Therapeutics said the MOONLIGHT-1 trial of JNJ-5120/PIPE-307 did not meet its primary efficacy goal in major depressive disorder. J&J is reviewing additional data, but the setback weakens the near-term pipeline contribution from the program. Johnson & Johnson-Partnered Contineum Depression Drug Fails Mid-Stage Trial
• Negative Sentiment: Reported insider activity shows executives have sold shares without any purchases during the past six months, a potentially cautionary sentiment signal, though such transactions may reflect diversification or scheduled sales rather than a fundamental view of JNJ.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.